{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"That's Derm Good!","title":"Why It’s Time to Rethink Hair Loss Solutions feat. Dr. Reid Waldman","html":"","width":"100%","height":180,"duration":1874,"description":"Dr. Reid Waldman, board-certified dermatologist and Founder & CEO of Veradermics, joins Janelle on That’s Derm Good! to talk about one of the most universal, and emotionally charged, topics in dermatology: hair loss.Dr. Waldman founded Veradermics after seeing countless patients devastated by hair thinning and frustrated with the lack of effective options. For decades, treatment for pattern hair loss has barely advanced, leaving millions feeling hopeless or misled by quick-fix products that rarely deliver visible results. In this episode, Dr. Waldman explains how his company is changing that narrative with a groundbreaking new treatment currently in late-stage clinical trials.DISCLAIMER: This podcast is for informational purposes only and should not be considered medical or health advice. This podcast does not substitute medical treatment. Always consult a doctor or dermatologist regarding medical advice, diagnoses, or treatmentThe conversation dives into Veradermics’ extended-release oral minoxidil tablet, designed to provide consistent hair growth results while minimizing the side effects often associated with traditional medications. Dr. Reid Waldman breaks down why this formulation could be the first major innovation in hair loss care in more than 30 years, and why it has the potential to become the first FDA-approved oral treatment for female pattern hair loss.Listeners will also hear insights on how clinical trials are conducted, what makes this research so challenging, and why education and early intervention are crucial. Dr. Waldman discusses the emotional side of hair loss, the need for honest patient conversations, and his hopes for setting new standards of care rooted in trust and evidence.ADVERTISER: A message from Sun Pharmaceuticals: For patients with locally advanced basal cell carcinoma who are not candidates for further surgery or radiation, hedgehog pathway inhibitors offer a targeted systemic approach. Staying current on these therapies can...","thumbnail_url":"https://img.transistorcdn.com/q9K2dcb1gwhr2ZV2_Xu4MjOSzqY1bfmmGoI-bTXCKm0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS82ZDJk/OWQ3OTRiYmU3ZjI2/YTQ1NDJmOWEzMTAx/Nzc3NC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}